News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
ICR welcomes olaparib approval by European Medicines Agency
The European Medicines Agency has approved olaparib for women with ovarian cancer who have a BRCA1 or BRCA2 mutation.
Highlights of the year, 2014
2014 has been full of exciting research results for the ICR. We have selected ten of our discoveries from the past year, which we'll publish every day over the next two weeks
Scientists discover way to target rare breast cancer mutation
UK scientists have identified a drug to target a rare breast cancer mutation that helps drive the disease in around 900 of the 50,000 new cases of breast cancer diagnosed in the UK each year.
ICR to collaborate with Merck Serono and Wellcome Trust to co-develop anti-cancer drugs
Merck Serono, The Institute of Cancer Research (ICR), and the Wellcome Trust, London, today announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.
ICR researchers focus on smart treatments at leading cancer conference
ICR scientists are making the trip to San Diego this weekend for one of the biggest dates in the cancer calendar – the American Association of Cancer Research (AACR) conference.
Gene prevents breast cancer spread by stopping cells becoming ‘sticky’
Scientists have discovered a gene that prevents the spread of breast cancer by stopping tumour cells from becoming ‘sticky’.
Study leads to new understandings of rare breast cancer type
A study into a unique breast cancer sub-type called micropapillary carcinoma of the breast has given new clues to its genetic make-up.
Beating breast cancer’s resistance to hormone treatments
Professor Clare Isacke discovered that a signalling pathway in ER-positive breast cancer that is linked to resistance to aromatase inhibitors in some cancers.
Latest breast cancer treatment advances presented at NCRI conference
Two researchers from The Institute of Cancer Research, London, have updated delegates at the UK's biggest cancer conference about the latest developments in breast cancer research.
Double-pronged attack overcomes bladder cancer’s drug resistance
Combining two different targeted therapies could greatly increase the effectiveness of bladder cancer treatments by blocking a tumour’s path to drug resistance, a new study reports.
Scientists identify new genetic driver for breast cancer
An over-active gene called GNAS may help drive the growth of some types of difficult-to-treat breast cancers, ICR scientists have found.
Tackling cancer’s biggest challenge: Combination treatments offer hope to overcome drug resistance
The huge genetic diversity within tumours is threatening efforts to create personalised cancer treatments – but, as an article in Nature Biotechnology reveals, scientists at The Institute of Cancer Research in London believe powerful new technology will bring a solution.
